O. Teherán , C. Parra , E. Ramos , M. Ochoa , W. Escobar
{"title":"加入肌霉素c的艾哈迈德瓣膜植入物在难治性青光眼患者随访一年的疗效评价。","authors":"O. Teherán , C. Parra , E. Ramos , M. Ochoa , W. Escobar","doi":"10.1016/j.oftale.2025.07.008","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>To evaluate the effectiveness and safety of mitomycin C (MMC) use when implanting Ahmed valve in patients with refractory glaucoma.</div></div><div><h3>Methods</h3><div>Cohort study involving 34 patients divided into two groups of 17 patients each: Group 1 (MMC use) and Group 2 (no MMC use), with a one-year follow-up. Complete success was defined as intraocular pressure (IOP) between 6−18 mmHg without the use of antiglaucoma medications; qualified success referred to the same IOP range but associated with antiglaucoma medications, while failure was characterized by IOP outside this range, severe complications or reintervention.</div></div><div><h3>Results</h3><div>The overall success rate in Group 1 was 88.2%, and in Group 2, 94.2%. There was an average reduction in IOP of 18.0-± 11.5 mmHg in Group 1 and 11.3 ± 5.0 mmHg in Group 2. The hypertensive phase occurred in 17.6% of the participants in the first group and the second, 70.6%.</div></div><div><h3>Conclusions</h3><div>The use of MMC decreases the hypertensive phase observed in Ahmed valve implant surgery, thereby achieving better IOP control.</div></div>","PeriodicalId":93886,"journal":{"name":"Archivos de la Sociedad Espanola de Oftalmologia","volume":"100 9","pages":"Pages 521-527"},"PeriodicalIF":0.0000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Evaluation of the effectiveness of Ahmed's valve implantation adding mitomicin C in patients with refractory glaucoma after one year of follow-up\",\"authors\":\"O. Teherán , C. Parra , E. Ramos , M. Ochoa , W. Escobar\",\"doi\":\"10.1016/j.oftale.2025.07.008\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Purpose</h3><div>To evaluate the effectiveness and safety of mitomycin C (MMC) use when implanting Ahmed valve in patients with refractory glaucoma.</div></div><div><h3>Methods</h3><div>Cohort study involving 34 patients divided into two groups of 17 patients each: Group 1 (MMC use) and Group 2 (no MMC use), with a one-year follow-up. Complete success was defined as intraocular pressure (IOP) between 6−18 mmHg without the use of antiglaucoma medications; qualified success referred to the same IOP range but associated with antiglaucoma medications, while failure was characterized by IOP outside this range, severe complications or reintervention.</div></div><div><h3>Results</h3><div>The overall success rate in Group 1 was 88.2%, and in Group 2, 94.2%. There was an average reduction in IOP of 18.0-± 11.5 mmHg in Group 1 and 11.3 ± 5.0 mmHg in Group 2. The hypertensive phase occurred in 17.6% of the participants in the first group and the second, 70.6%.</div></div><div><h3>Conclusions</h3><div>The use of MMC decreases the hypertensive phase observed in Ahmed valve implant surgery, thereby achieving better IOP control.</div></div>\",\"PeriodicalId\":93886,\"journal\":{\"name\":\"Archivos de la Sociedad Espanola de Oftalmologia\",\"volume\":\"100 9\",\"pages\":\"Pages 521-527\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Archivos de la Sociedad Espanola de Oftalmologia\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2173579425001240\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archivos de la Sociedad Espanola de Oftalmologia","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2173579425001240","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Evaluation of the effectiveness of Ahmed's valve implantation adding mitomicin C in patients with refractory glaucoma after one year of follow-up
Purpose
To evaluate the effectiveness and safety of mitomycin C (MMC) use when implanting Ahmed valve in patients with refractory glaucoma.
Methods
Cohort study involving 34 patients divided into two groups of 17 patients each: Group 1 (MMC use) and Group 2 (no MMC use), with a one-year follow-up. Complete success was defined as intraocular pressure (IOP) between 6−18 mmHg without the use of antiglaucoma medications; qualified success referred to the same IOP range but associated with antiglaucoma medications, while failure was characterized by IOP outside this range, severe complications or reintervention.
Results
The overall success rate in Group 1 was 88.2%, and in Group 2, 94.2%. There was an average reduction in IOP of 18.0-± 11.5 mmHg in Group 1 and 11.3 ± 5.0 mmHg in Group 2. The hypertensive phase occurred in 17.6% of the participants in the first group and the second, 70.6%.
Conclusions
The use of MMC decreases the hypertensive phase observed in Ahmed valve implant surgery, thereby achieving better IOP control.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
